• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Psychemedics Releases 2025 Workforce Insights Report

    6/16/25 9:00:00 AM ET
    $PMD
    Medical Specialities
    Health Care
    Get the next $PMD alert in real time by email

    DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk.

    The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industry, analyzing hundreds of thousands of samples collected in 2024 across a wide range of sectors, including transportation, manufacturing, healthcare, government, and more. The report reveals critical workforce trends and emerging threats employers must navigate in today's rapidly changing drug climate.

    Key findings from the 2025 report include:

    • Synthetic opioids on the rise: Fentanyl remains a top concern, with increasing detection of ultra-potent nitazenes, some up to 20x stronger than fentanyl.
    • Healthcare and manufacturing industries at highest risk: Positive drug test rates reached 14.7% and 14.6%, respectively.
    • Resurgence of cocaine and methamphetamine: Notable increases in stimulant use, particularly in high-pressure industries.
    • Legal marijuana and high THC potency: States with legalized recreational cannabis saw a 10% increase in workplace injuries among young workers.
    • Hair testing remains the most reliable method, offering a 90-day detection window and unmatched resistance to evasion, making it the gold standard for long-term drug detection.

    "As the drug landscape evolves, with new synthetic substances, rising marijuana potency, and shifting laws, employers are under growing pressure to maintain safe, compliant, and productive workplaces," said Brian Hullinger, President and CEO of Psychemedics.

    The 2025 report emphasizes the need for comprehensive drug testing strategies that extend beyond detection to include education, prevention, and support. By offering deep insight into five-year trends and sector-specific risks, Psychemedics equips employers with the tools to adapt policies, mitigate liability, and make informed decisions.

    The full 2025 Workforce Insights Report is available at: https://www.psychemedics.com/whitepaper/

    For more information about Psychemedics Corporation and its innovative hair testing solutions, visit https://www.psychemedics.com.

    About Psychemedics 

    Psychemedics Corporation is a leading global provider of innovative hair testing for drugs of abuse. With a commitment to accuracy and reliability, the company offers cutting-edge drug testing solutions. Psychemedics Corporation is dedicated to providing valuable insights and maintaining the highest standards in substance abuse testing.

    Investor Relations:

    Phone: 978-206-8220

    Email: [email protected]



    Primary Logo

    Get the next $PMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMD
    SEC Filings

    See more
    • SEC Form 15-12G filed by Psychemedics Corporation

      15-12G - PSYCHEMEDICS CORP (0000806517) (Filer)

      1/2/25 4:10:54 PM ET
      $PMD
      Medical Specialities
      Health Care
    • SEC Form 25 filed by Psychemedics Corporation

      25 - PSYCHEMEDICS CORP (0000806517) (Filer)

      12/13/24 8:00:57 AM ET
      $PMD
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13E3/A filed by Psychemedics Corporation

      SC 13E3/A - PSYCHEMEDICS CORP (0000806517) (Subject)

      12/10/24 4:46:00 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Psychemedics Releases 2025 Workforce Insights Report

      DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk. The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industry, analyzing hundreds of thousands of samples collected in 2024 across a wide range of sectors, including transportation, manufacturing, healthcare, government, and more. The report reveals critical workforce trends and emerging threats empl

      6/16/25 9:00:00 AM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing Insights

      DALLAS, March 03, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair drug testing, is proud to announce the launch of its innovative Quartile Reporting feature. This industry-first enhancement empowers organizations with unprecedented insights into drug test results, enabling data-driven decision-making and fostering safer, more productive workplaces. The new Quartile Reporting feature allows clients to see where a candidate's or employee's test results fall within a range of positive reports collected over the past 12 months. By segmenting results into four quartiles – Lower, Median, Upper, and Highest – this advanced reporting provides real-time context and bench

      3/3/25 9:00:00 AM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Corporation Announces Reverse and Forward Stock Split

      DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) (the "Company"), the world's leading provider of hair testing for drugs of abuse, today announced that, following the approval of the Company's stockholders at its Annual Meeting of Stockholders held on November 25, 2024, the Company's Board of Directors has approved a 1-for-5,000 reverse stock split of its common stock (the "Reverse Stock Split") followed immediately by a 5,000-for-1 forward stock split of its common stock (the "Forward Stock Split," and together with the Reverse Stock Split, the "Stock Split"), to be effective at 5:01 p.m. and 5:02 p.m., Eastern Time, respectively, on Tuesday, December 3, 202

      12/2/24 8:10:00 AM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Financials

    Live finance-specific insights

    See more
    • Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen

      ACTON, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to the paramount threat of fentanyl. Complemented by the detection of cocaine, opioids, PCP, and amphetamines, the advanced panel is a leap forward in drug screening technology. As we grapple with an ongoing labor shortage and with marijuana's legal landscape evolving in 49 states, it's clear that the time for

      10/27/23 11:00:00 AM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Corporation Reports Second Quarter 2023 Financial Results

      ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023. The Company's revenue for the quarter ended June 30, 2023, was $5.5 million versus $6.5 million for the quarter ended June 30, 2022, a decrease of 15%. Net loss for the quarter ended June 30, 2023, was $(726,000) or $(0.13) per diluted share, versus net loss of $(338,000) or $(0.06) per diluted share, for the comparable period last year. In the second quarter, the labor shortage continued to have an adverse impact on our clients' use of hair testing in hirin

      8/11/23 5:10:31 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Corporation Reports First Quarter 2023 Financial Results and Declares Cash Dividend

      ACTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2023, and the declaration of a cash dividend of $0.07 per share to be paid on June 8, 2023, to shareholders of record as of May 25, 2023. The Company's revenue for the quarter ended March 31, 2023, was $5.9 million versus $6.5 million for the quarter ended March 31, 2022, a decrease of 10%. Net loss for the quarter ended March 31, 2023, was $(384,000) or $(0.07) per diluted share, versus net income of $39,000 or $0.01 per diluted share, for the comparable period last ye

      5/9/23 5:30:00 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

      ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in steering the financial trajectory of the organization. Bringing over a decade of extensive experience to her new position, Ms. Mehalik possesses a robust background in acco

      11/27/23 9:00:00 AM ET
      $NBSE
      $PMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Psychemedics Corporation Reports Third Quarter 2023 Financial Results

      ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company's revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net loss of $(97,000) or $(0.02) per diluted share, for the comparable period last year. The Company has initiated a series of restructuring changes that will align costs with current revenue trends. Res

      11/9/23 5:00:59 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

      ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world's largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies. With an exceptional track record of leadership and a strong background in revenue growth and optimization, Shoemaker brings a wealth of experience to her new position. Her appointment marks a significant milestone for Psychemedics Corporation as it continues to expand its presence in the rapidly evolving field of substance abuse testing. "We are

      9/21/23 5:00:00 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

      SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

      12/12/24 5:15:40 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Psychemedics Corporation

      SC 13G/A - PSYCHEMEDICS CORP (0000806517) (Subject)

      12/6/24 9:18:20 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

      SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

      12/5/24 6:04:48 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/17/24 8:29:49 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/12/24 8:41:51 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Director Kamin Peter sold $753,664 worth of shares (320,708 units at $2.35) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/12/24 5:15:34 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/17/24 8:29:49 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/12/24 8:41:51 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Director Kamin Peter bought $3,312,823 worth of shares (1,409,712 units at $2.35) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/5/24 6:05:08 PM ET
      $PMD
      Medical Specialities
      Health Care